Experience

• Ms. Fox has represented either the issuer or the underwriters in numerous IPOs, follow-on offerings and other equity and debt offerings, including the following:

  • State Street Corporation in numerous offerings of senior and subordinated notes and its $1.5 billion preferred stock offering
  • Thermo Fisher Scientific in numerous debt offerings, including its $2.95 billion senior notes offering, its $1.2 billion USD and €1.25 billion EUR notes offerings  and its inaugural CHF 1.07 billion offering of bonds on the SIX Swiss Exchange
  • Astria Therapeutics in its $125 million underwritten registered direct offering
  • Danaher Corporation and Veralto Corporation in Veralto’s $2.1 billion senior notes offering and €500 million senior notes offering
  • Eastman Chemical in its inaugural $500 million green bond offering and its $750 million senior notes offering
  • Xilio Therapeutics in its $130 million initial public offering and in several private placement equity financings
  • Cue Health in its $200 million initial public offering
  • Viridian Therapeutics in its $98 million follow-on public offering
  • Rallybio in its $93 million initial public offering
  • Kymera Therapeutics in its $200 million initial public offering and $257 million follow-on public offering
  • Akouos in its $244 million initial public offering
  • Generation Bio in its $230 million initial public offering
  • IVERIC bio in its follow-on public offering of common stock and pre-funded warrants to purchase common stock
  • Arvinas in its $115 million follow-on public offering
  • Thermo Fisher Scientific in concurrent public offerings of €4.4 billion aggregate principal amount of euro-denominated notes and $900 million aggregate principal amount of USD-denominated notes
  • Akamai in 144A offerings of convertible senior notes for $1.1 billion and $1.15 billion
  • Danaher Corporation in concurrent follow-on public offerings of $1.44 billion of common stock and $1.60 billion of mandatory convertible preferred stock
  • Epizyme in numerous follow-on public offerings, including its March 2019 $172.5 million concurrent public offerings of common stock and preferred stock
  • Epizyme in its establishment of funding agreements with Royalty Pharma and its affiliate for up to $270 million, including an expandable loan facility
  • Syros Pharmaceuticals in its $70 million concurrent follow-on public offerings
  • HubSpot in its $144 million initial public offering and $167 million follow-on public offering
  • Imprivata in its $86 million initial public offering and $79 million secondary offering
  • Biotie Therapies in its $64 million initial public offering, the first U.S. IPO of a Finnish company in over more than 20 years
  • Nabriva Therapeutics in its $106 million initial public offering
  • Demandware in its $101 million initial public offering
  • TechTarget in its $115 million initial public offering and in its $36 million secondary offering